COVID-19 and immunomodulation treatment for women with reproductive failures
Autor
Kwak-Kim, Joanne
Ota, Kuniaki
Sung, Nayoung
Huang, Changsheng
Alsubki, Lujain
Lee, Sungki
Won Han, Jae
Han, Aera
Yang, Xiuhua
Saab, Wael
Derbala, Youssef
Wang, Wen-Juan
He, Qiaohua
Liao, Aihua
Takahashi, Toshifumi
Borges Cavalcante, Marcelo
Barini, Ricardo
Bao, Shihua
Fukui, Atsushi
Lédée, Nathalie
Coulam, Carolyn
Institución
Resumen
COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with
reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using
immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during
the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and
active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to
review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for
immunotherapy in women with reproductive failures.